| pubmed-article:16210961 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16210961 | lifeskim:mentions | umls-concept:C0376387 | lld:lifeskim |
| pubmed-article:16210961 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:16210961 | lifeskim:mentions | umls-concept:C0022671 | lld:lifeskim |
| pubmed-article:16210961 | lifeskim:mentions | umls-concept:C0072980 | lld:lifeskim |
| pubmed-article:16210961 | lifeskim:mentions | umls-concept:C0205251 | lld:lifeskim |
| pubmed-article:16210961 | lifeskim:mentions | umls-concept:C0021149 | lld:lifeskim |
| pubmed-article:16210961 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:16210961 | pubmed:dateCreated | 2005-10-7 | lld:pubmed |
| pubmed-article:16210961 | pubmed:abstractText | Malignancies, a well-known complication of immunosuppressive therapy in renal transplant recipients, represent an important cause of long-term morbidity and mortality. One approach to addressing this problem is identifying agents that display antineoplastic properties concomitant with their immunosuppressive effects. | lld:pubmed |
| pubmed-article:16210961 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16210961 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16210961 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16210961 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16210961 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16210961 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16210961 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16210961 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16210961 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:16210961 | pubmed:issn | 0041-1337 | lld:pubmed |
| pubmed-article:16210961 | pubmed:author | pubmed-author:KahanBarry... | lld:pubmed |
| pubmed-article:16210961 | pubmed:author | pubmed-author:Van... | lld:pubmed |
| pubmed-article:16210961 | pubmed:author | pubmed-author:KatzStephen... | lld:pubmed |
| pubmed-article:16210961 | pubmed:author | pubmed-author:KnightRichard... | lld:pubmed |
| pubmed-article:16210961 | pubmed:author | pubmed-author:SchoenbergLin... | lld:pubmed |
| pubmed-article:16210961 | pubmed:author | pubmed-author:YakupogluYark... | lld:pubmed |
| pubmed-article:16210961 | pubmed:author | pubmed-author:LaiDeijanD | lld:pubmed |
| pubmed-article:16210961 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16210961 | pubmed:day | 27 | lld:pubmed |
| pubmed-article:16210961 | pubmed:volume | 80 | lld:pubmed |
| pubmed-article:16210961 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16210961 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16210961 | pubmed:pagination | 749-58 | lld:pubmed |
| pubmed-article:16210961 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:meshHeading | pubmed-meshheading:16210961... | lld:pubmed |
| pubmed-article:16210961 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16210961 | pubmed:articleTitle | Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. | lld:pubmed |
| pubmed-article:16210961 | pubmed:affiliation | The University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA. Barry.D.Kahan@uth.tmc.edu | lld:pubmed |
| pubmed-article:16210961 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16210961 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16210961 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16210961 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16210961 | lld:pubmed |
